In the third quarter of 2024, the Company made difficult, but essential, decisions to align with its renewed focus. Notably, SINTX made the decision to cease operations of its armor division and recorded a one-time $4.5 million impairment charge.

This move aligns with SINTX's emphasis on reallocating resources towards the medical device market, where the Company sees the greatest potential for impactful, sustainable growth.

Additionally, a reduction in workforce during Q3 positions the company for a leaner, more efficient structure, supporting ongoing cost optimization efforts.